论文信息 - Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation - 字舞流文

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

F. Accurso | M. Ashlock | M. Konstan | Karl Yen | S. Willsie | S. Wisseh | A. Leonard | I. Bronsveld | D. Rosenbluth | C. Ordoñez | Manu Jain | J. P. Clancy | Henry L. Dorkin | Karen S. McCoy | Steven M. Rowe | Michael P. Boyle | Raouf S Amin | Richard B. Moss | Preston W Campbell | Scott H Donaldson | Jordan M. Dunitz | Peter R Durie | Joseph M. Pilewski | George T Spencer-Green | Laurent Vernillet | Moira L. Aitken | Ronald C. Rubenstein | M. Schechter | Manfred Ballmann | K. D. Boeck | Martyn Botfield | J. M. Dunitz | Martyn C. Botfield